Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease
- PMID: 12124237
- DOI: 10.1259/bjr.75.894.750506
Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease
Abstract
A surrogate marker is needed for Alzheimer's disease (AD) both to aid diagnosis and to assess interventions. Despite widespread use, brain imaging markers have largely been confounded by overlap with "normal" ageing. 39 elderly subjects completed up to four serial volumetric brain MRI scans with intervals from 2.5 months to 7 months. By National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria, five subjects had probable AD, two possible AD and 32 were negative for AD, although this group included memory-impaired subjects. Total brain and ventricular volumes were measured for each scan, and rates of change for each interval calculated. The rate of change in ventricle-to-brain ratio was 15.6% per year (standard deviation (SD) 2.8%) for probable AD compared with 4.3% per year (SD 1.1%) for negative AD (p<0.001). There was no significant difference between these groups' mean ventricle-to-brain ratios measured at a single time point (p=0.25). Rates of change in brain or ventricular volume over time also differed between the two groups (p<0.001). Power calculations reveal that to detect a 20% reduction in the excess rate of atrophy of a probable AD cohort in just 6 months, with 90% power, 135 subjects would be required in each arm of a randomized placebo controlled trial. For a 30% reduction in the excess rate of atrophy, 61 subjects would be required. Rate of change analysis makes serial brain MRI a valuable surrogate marker for Alzheimer's disease. Since only 6 months or less is required between scans, this procedure has both clinical relevance and potential for monitoring interventions.
Similar articles
-
Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months.Neurology. 2005 Jul 12;65(1):119-24. doi: 10.1212/01.wnl.0000167542.89697.0f. Neurology. 2005. PMID: 16009896
-
Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials.J Neurol. 2006 Sep;253(9):1147-53. doi: 10.1007/s00415-006-0173-4. Epub 2006 Sep 22. J Neurol. 2006. PMID: 16998650
-
MRI and CSF studies in the early diagnosis of Alzheimer's disease.J Intern Med. 2004 Sep;256(3):205-23. doi: 10.1111/j.1365-2796.2004.01381.x. J Intern Med. 2004. PMID: 15324364
-
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.Arch Neurol. 2000 Mar;57(3):339-44. doi: 10.1001/archneur.57.3.339. Arch Neurol. 2000. PMID: 10714659
-
Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease.Med Clin North Am. 2013 May;97(3):399-424. doi: 10.1016/j.mcna.2012.12.013. Epub 2013 Feb 1. Med Clin North Am. 2013. PMID: 23642578 Review.
Cited by
-
Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies.Neuroimage Clin. 2015 Feb 7;7:456-62. doi: 10.1016/j.nicl.2015.01.017. eCollection 2015. Neuroimage Clin. 2015. PMID: 25685712 Free PMC article.
-
Cognitive Correlates of Hippocampal Atrophy and Ventricular Enlargement in Adults with or without Mild Cognitive Impairment.Dement Geriatr Cogn Dis Extra. 2019 Aug 13;9(2):281-293. doi: 10.1159/000490044. eCollection 2019 May-Aug. Dement Geriatr Cogn Dis Extra. 2019. PMID: 31572424 Free PMC article.
-
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.J Prev Alzheimers Dis. 2022;9(4):780-790. doi: 10.14283/jpad.2022.63. J Prev Alzheimers Dis. 2022. PMID: 36281683 Free PMC article. Clinical Trial.
-
Status epilepticus as a risk factor for postencephalitic parenchyma loss evaluated by ventricle brain ratio measurement on MR imaging.AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1245-51. AJNR Am J Neuroradiol. 2006. PMID: 16775274 Free PMC article.
-
The role of biomarkers in clinical trials for Alzheimer disease.Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15. doi: 10.1097/01.wad.0000191420.61260.a8. Alzheimer Dis Assoc Disord. 2006. PMID: 16493230 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical